TP53 and acute myeloid leukemia: Like MDS or AML arising after autologous HCT, preexisting clones carrying the TP53 or PPM1D mutation may give rise to MDS or AML in patients after gene therapy or in recipients of allogeneic HCT who rejected their grafts.